Mannkind MNKD Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

Boston ScientificBSX

-$30M-700%

Merit Medical SystemsMMSI

——

Other financials

Income statement

See full

Revenue$90.2M+15.1%

Gross profit$82.7M+10.8%

Operating income-$1.7M-107%

Net income-$16.6M-226%

EPS (diluted)-$0.05-225%

Balance sheet

See full

Cash & equivalents$52.8M+11.7%

Total debt$12.2M-9.4%

Total equity-$59.2M-1.0%

Total assets$744.4M+81.5%

Cash flow

See full

Operating cash flow-$5.4M+15.9%

CapEx$1.9M+470%

Free cash flow-$7.2M-8.0%

Valuation

See full

Market cap$1.19B+3.5%

Enterprise value$1.15B+3.0%

P/E228.5×—

P/S3.3×-0.6×

Profitability

See full

Gross margin91.5%-2.6pp

Operating margin23.3%+3.1pp

Net margin9.3%—

FCF margin13.8%—

Returns & leverage

See full

Return on equity-8.8%—

Debt / equity-0.2×—

Current ratio1.9×-0.5×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Mannkind’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mannkind's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Mannkind's contingent consideration fair value adjustments?: Mannkind (MNKD) reported contingent consideration fair value adjustments of $257.25K in Q4 2025.